Gan & Lee Receives the US FDA’s Fast Track Designation for GLR2007 for the Treatment of Patients with Glioblastoma

February 1, 2021 Auto Bot Fast Track Designation, FDA, Gan & Lee, patients, receives, regulatory, Treatment 0

Shots:

  • The US FDA has granted FTD for GLR2007 for the treatment of patients with glioblastoma and application is eligible for Rolling Review and for Accelerated Approval and Priority Review
  • The Designation evaluate to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need
  • GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor for the treatment of advanced solid tumors including glioblastoma, an aggressive form of brain cancer with a low survival rate

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Gan & Lee

The post Gan & Lee Receives the US FDA’s Fast Track Designation for GLR2007 for the Treatment of Patients with Glioblastoma first appeared on PharmaShots.